[Maintenance of the activation of peritoneal macrophage in patients with ovarian cancer by the repeated administration of sizofiran and interferon gamma].
Four patients with ovarian cancer were treated with a 20mg injection of sizofiran, a MW 450,000 beta-1,3-glucan, intramuscularly one day before and 4,7,11,14,18 and 21 days after second look laparotomy and with the administration of 2 million units of interferon gamma intraperitoneally at 0,4,7,11,14,18 and 21 days after second look laparotomy. Peritoneal macrophages were obtained from the patients by peritoneal washing with saline through an indwelled tube. The number of macrophages was increased to about 30 times after the treatment. The concentrations of interleukin 1, interferon gamma, tumor necrosis factor and prostaglandin E2 in the media of 24-hour cultured macrophage with 10 micrograms/ml of LPS were also increased throughout the treatment. These data suggest that the every 3 to 4 day treatment with sizofiran and interferon gamma maintained the activation of peritoneal macrophages which might lead to retention of the antitumor activity in patients with ovarian cancer.
Chen
J T
JT
Department of Gynecology, Cancer Institute Hospital, Tokyo.
Hasumi
K
K
Masubuchi
K
K
D000328:Adult; D003536:Cystadenocarcinoma / Q000276:immunology / Q000628:therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000008:administration & dosage*; D007375:Interleukin-1 / Q000096:biosynthesis; D008262:Macrophage Activation / Q000502:physiology*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy*; D010529:Peritoneal Cavity / Q000166:cytology; D012566:Sizofiran / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D012566:Sizofiran; D007371:Interferon-gamma